Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

OTHER 5INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 2Gastrointestinal 1

Conditions

Neoplasms 2Solid Tumors 1Pancreatic Adenocarcinoma 1Advanced/Metastatic Solid Tumors 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × selicrelumab × Clear all
NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02665416 2020-04-07

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
94 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT02304393 2019-12-13

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
140 enrolled
Other solid neoplasm

Solid Tumors

NCT02760797 2018-05-22

A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
38 enrolled
Tumor-Agnostic

Neoplasms

NCT00607048 2017-03-27

Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
34 enrolled 18 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡